Loading...
DOCUMENTS
20
NOTICES
32
MOTS CLES
Stricture
Ustekinumab
Colon
Tuberculosis
Effectiveness
Cost effectiveness
Fecal microbiota
Methylation
Anti-TNF
Primary sclerosing cholangitis
Drug
Thérapie ciblée
Colorectal cancer Colibactin and lipids
T1118 translocation
Patient-reported outcome
Immunosuppressant
Immune cells
Inflammatory bowel diseases
IL12
Monitoring
Contraindication
Crohn's disease
Safety
Méthylation
Resistance
Clinical guidelines
18 FDG-PET/CT
Kidney diseases
Anti-TNF agents
Virulent bacteria
MORTALITY
Cell adhesion
Neoadjuvant chemotherapy
MARKER
Venous thromboembolism
Upper gastrointestinal tract
Survival
MALT
Colorectal cancer
Alkylating agents
DNA methylation
Disease progression
Éradication
CARCINOGENESIS
Eligibility
Microbiote
Parvimonas micra
Inflammatory bowel disease
Genes
MICROBIOTA
Inclusion
Heart disease risk factors
Gene expression
DNA METHYLATION
Gene methylation
Maintenance therapy
Screening
RISK
Microbiota
IBD
Crohn’s disease
Original Article Clinical
Tailored therapy
Intestinal crypts
Gènes
Small molecules
Colonic epithelial primary cells
Endoscopic treatment
Bacteria
Epigénétiques
Biomarker
Algorithm
PCR
Consensus
Disability
Vedolizumab
Patients experience
Dysbiosis
COLON-CANCER
Epigenetics
Acceptability
Dysbiose
Inhibitor
Biologics
Rituximab plus chlorambucil
Bactéries
Colectomy
Cancer
Over 80s
Eradication
Ulcerative colitis
Surgery
Rituximab
Helicobacter pylori
Clinical trial
Colon cancer
Résistance
IL23
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|